Ovid Therapeutics sees cash runway into 2H26

Ovid expects its cash runway to support operations and clinical development programs into early second half 2026, during which time multiple pipeline and regulatory milestones are anticipated. These anticipated milestones include topline results for OV329 safety, tolerability and biomarker data Q3 2025; potential initiation of a Phase 2a patient study for OV329 in drug-resistant epilepsies Q1 2026; results from the Phase 1 study of OV350 Q4 2025; and the potential initiation of a proof-of-concept trial for the first oral KCC2 direct activator, OV4071 Q2 2026. Given the breadth and depth of its pipeline, and the broad therapeutic opportunity it may yield, the Company will continue to explore a range of strategic options to accelerate development and offset costs, such as partnerships, co-development and regional opportunities for select programs, as well as monetizing equity positions, intellectual property and non-CNS applications of its candidates. The Company will continue to manage its clinical development programs, operations and cash expenditures with fiscal discipline to support the potential achievement of key value-creating clinical milestones.